Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5504 Citation: J Clin Oncol 35, 2017...
LION: Lymphadenectomy in ovarian neoplasms – A prospective randomized AGO study group led gynecologic cancer intergroup trial
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Abstract number: 5500 Citation: J Clin Oncol 35,...
Strategic Combinations in Ovarian Cancer
29 septembra, 2020 8:30 pm Leave your thoughtsJune 3, 2017 The introduction of PARP inhibitors revolutionized the treatment of ovarian cancer, providing much-needed therapeutic options. However,...
Gynekologické malignity – stručný výber z prác prezentovaných na ASCO Annual Meeting 2017
29 septembra, 2020 8:30 pm Leave your thoughtsÚvod Od 2. do 6. júna 2017 sa konal v Chicagu výročný kongres American Society of Clinical Oncology (ASCO), na ktorom sa stretlo viac...
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: 501 Citation: J Clin Oncol...
A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03)
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Abstract number: 507 Citation: J Clin Oncol 35,...
Phase II study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer-Metastatic Abstract number: 1008 Citation: J Clin Oncol 35, 2017...
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Title:Breast Cancer-Metastatic Abstract number: 1002 Citation: J Clin Oncol 35, 2017...
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: LBA500 Citation: J Clin Oncol...
Pertuzumab Reduced Risk of Invasive Disease–Free Survival Compared With Placebo in APHINITY
29 septembra, 2020 8:30 pm Leave your thoughtsJune 5, 2017 Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to...